ProPhase Labs Change in Assets/Liabilities 2010-2025 | PRPH

ProPhase Labs change in assets/liabilities from 2010 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities

ProPhase Labs Change in Assets/Liabilities 2010-2025 | PRPH

ProPhase Labs change in assets/liabilities from 2010 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$82.2B
Zoetis (ZTS)$67.6B
Daiichi Sankyo, - (DSNKY)$46.9B
Takeda Pharmaceutical (TAK)$45.4B
BeOne Medicines - (ONC)$33.4B
Sandoz Group AG (SDZNY)$25.2B
Summit Therapeutics (SMMT)$21.8B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$14.7B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$12.7B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.6B
Grifols, S.A (GRFS)$7.4B
Madrigal Pharmaceuticals (MDGL)$6.9B
Ionis Pharmaceuticals (IONS)$6.9B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.2B
Hypermarcas (HYPMY)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.7B
Crinetics Pharmaceuticals (CRNX)$2.6B
Procaps Group, S.A (PROCF)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$2B
BioCryst Pharmaceuticals (BCRX)$1.8B